DMAC · DiaMedica Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Jan Stahlberg 10% Owner | ▲ Buy | Open Market | 8,825,742 Shares held | 11/25/2025 | View profile |
| Von Koch Thomas 10% Owner | ▲ Buy | Open Market | 8,383,577 Shares held | 7/23/2025 | View profile |
| Richard Jacinto II 10% Owner | ▲ Buy | Open Market | 4,958,823 Shares held | 7/23/2025 | View profile |
| David J. Wambeke Chief Business Officer | ▲ Buy | Open Market | 527,114 Shares held | 11/16/2023 | View profile |
| Randall Michael Giuffre Director | ▲ Buy | Grant | 398,587 Shares held | 1/2/2026 | View profile |
| Richard D. Pilnik Director | ▲ Buy | Option Exercise | 312,995 Shares held | 4/7/2025 | View profile |
| Dietrich John Pauls President and CEO | ▲ Buy | Grant | 128,791 Shares held | 8/10/2026 | View profile |
| James T. Parsons Director | ▲ Buy | Grant | 97,949 Shares held | 1/2/2026 | View profile |
| Burroughs Amy L. Director | ▲ Buy | Grant | 73,288 Shares held | 1/3/2023 | View profile |
| Charles Pauling Semba Director | ▲ Buy | Grant | 47,963 Shares held | 1/2/2026 | View profile |
| ALCORN HARRY W JR SVP, Clinical Operations | ▲ Buy | Open Market | 43,582 Shares held | 9/15/2021 | View profile |
| Kellen Scott CFO and Secretary | ▲ Buy | Open Market | 32,290 Shares held | 6/23/2023 | View profile |
| Richard Kuntz SVP & Chief Medical & Science | ▲ Buy | Grant | 24,210 Shares held | 1/2/2025 | View profile |
Transaction History
| Dietrich John Pauls | ▲ Buy | Grant | 60,200 | $0 | 8/10/2026 |
| James T. Parsons | ▲ Buy | Grant | 10,095 | $85K | 1/2/2026 |
| Randall Michael Giuffre | ▲ Buy | Grant | 6,175 | $52K | 1/2/2026 |
| Charles Pauling Semba | ▲ Buy | Grant | 3,355 | $28K | 1/2/2026 |
| Jan Stahlberg | ▲ Buy | Open Market | 73,099 | $627K | 11/25/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 40,253 | $318K | 11/24/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 208,872 | $1.5M | 11/21/2025 |
| James T. Parsons | ▲ Buy | Option Exercise | 12,000 | $26K | 11/21/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 128,426 | $951K | 11/20/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 240,352 | $1.7M | 11/19/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 182,882 | $1.2M | 11/18/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 187,393 | $1.2M | 11/17/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 50,772 | $305K | 8/27/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 59,648 | $358K | 8/26/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 338,265 | $2.0M | 8/25/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 59,788 | $357K | 8/22/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 48,172 | $287K | 8/21/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 71,107 | $416K | 8/20/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 8,233 | $49K | 8/15/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 70,414 | $422K | 8/14/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 293,601 | $1.7M | 8/13/2025 |
| Jan Stahlberg | ▲ Buy | Open Market | 1,542,857 | $5.4M | 7/23/2025 |
| Von Koch Thomas | ▲ Buy | Open Market | 2,857,142 | $10.0M | 7/23/2025 |
| Richard Jacinto II | ▲ Buy | Open Market | 400,000 | $1.4M | 7/23/2025 |
| Richard D. Pilnik | ▲ Buy | Option Exercise | 24,000 | $51K | 4/7/2025 |
| Randall Michael Giuffre | ▲ Buy | Option Exercise | 12,000 | $25K | 2/13/2025 |
| Randall Michael Giuffre | ▲ Buy | Option Exercise | 5,000 | $18K | 2/13/2025 |
| James T. Parsons | ▲ Buy | Grant | 15,917 | $85K | 1/2/2025 |
| Randall Michael Giuffre | ▲ Buy | Grant | 10,861 | $58K | 1/2/2025 |
| Richard Kuntz | ▲ Buy | Grant | 9,925 | $53K | 1/2/2025 |
| Richard D. Pilnik | ▲ Buy | Grant | 10,393 | $55K | 1/2/2025 |
| Charles Pauling Semba | ▲ Buy | Grant | 5,290 | $28K | 1/2/2025 |
| Von Koch Thomas | ▲ Buy | Open Market | 1,200,000 | $3.0M | 6/28/2024 |
| Jan Stahlberg | ▲ Buy | Open Market | 1,200,000 | $3.0M | 6/28/2024 |
| Charles Pauling Semba | ▲ Buy | Grant | 9,375 | $26K | 1/2/2024 |
| Richard D. Pilnik | ▲ Buy | Grant | 30,357 | $85K | 1/2/2024 |
| Richard Kuntz | ▲ Buy | Grant | 14,285 | $40K | 1/2/2024 |
| James T. Parsons | ▲ Buy | Grant | 21,428 | $60K | 1/2/2024 |
| Randall Michael Giuffre | ▲ Buy | Grant | 19,196 | $54K | 1/2/2024 |
| David J. Wambeke | ▲ Buy | Open Market | 20,000 | $49K | 11/16/2023 |
| David J. Wambeke | ▲ Buy | Open Market | 38,364 | $150K | 6/23/2023 |
| Richard D. Pilnik | ▲ Buy | Open Market | 38,363 | $150K | 6/23/2023 |
| Dietrich John Pauls | ▲ Buy | Open Market | 12,787 | $50K | 6/23/2023 |
| Kellen Scott | ▲ Buy | Open Market | 10,000 | $39K | 6/23/2023 |
| Charles Pauling Semba | ▲ Buy | Open Market | 12,787 | $50K | 6/23/2023 |
| Randall Michael Giuffre | ▼ Sell | Gift | 15,000 | $0 | 6/23/2023 |
| Von Koch Thomas | ▲ Buy | Open Market | 1,470,588 | $5.0M | 6/23/2023 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 65,000 | $254K | 6/23/2023 |
| David J. Wambeke | ▲ Buy | Open Market | 468,750 | $750K | 4/10/2023 |
| Burroughs Amy L. | ▲ Buy | Grant | 17,156 | $26K | 1/3/2023 |
| Randall Michael Giuffre | ▲ Buy | Grant | 35,130 | $54K | 1/3/2023 |
| Charles Pauling Semba | ▲ Buy | Grant | 17,156 | $26K | 1/3/2023 |
| Richard D. Pilnik | ▲ Buy | Grant | 55,555 | $85K | 1/3/2023 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 37,079 | $53K | 12/9/2022 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 20,000 | $28K | 12/8/2022 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 22,574 | $32K | 12/7/2022 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 2,300 | $3K | 12/6/2022 |
| Richard D. Pilnik | ▲ Buy | Open Market | 35,000 | $48K | 12/5/2022 |
| Von Koch Thomas | ▼ Sell | Open Market | 2,855,847 | $3.5M | 12/2/2022 |
| Von Koch Thomas | ▲ Buy | Open Market | 2,855,847 | $3.5M | 12/2/2022 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 819 | $975 | 12/1/2022 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 46,133 | $55K | 12/1/2022 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 2,970 | $4K | 11/30/2022 |
| Randall Michael Giuffre | ▲ Buy | Open Market | 18,125 | $22K | 11/29/2022 |
| Dietrich John Pauls | ▲ Buy | Open Market | 20,000 | $24K | 11/16/2022 |
| Von Koch Thomas | ▲ Buy | Open Market | 207,974 | $276K | 7/8/2022 |
| Randall Michael Giuffre | ▲ Buy | Grant | 15,026 | $54K | 1/3/2022 |
| James T. Parsons | ▲ Buy | Grant | 16,773 | $60K | 1/3/2022 |
| Richard D. Pilnik | ▲ Buy | Grant | 23,762 | $85K | 1/3/2022 |
| Burroughs Amy L. | ▲ Buy | Grant | 11,182 | $40K | 1/3/2022 |
| ALCORN HARRY W JR | ▲ Buy | Open Market | 15,000 | $57K | 9/15/2021 |
| Burroughs Amy L. | ▲ Buy | Open Market | 44,950 | $142K | 8/16/2021 |
| Richard D. Pilnik | ▲ Buy | Open Market | 2,500 | $8K | 8/16/2021 |
| Richard D. Pilnik | ▲ Buy | Open Market | 12,500 | $41K | 8/16/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction
DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.